November 14, 2018
The College, the American Academy of Allergy, Asthma and Immunology (AAAAI) and the American Academy of Otolaryngic Allergy (AAOA) have provided feedback to the United States Pharmacopeia (USP) on the proposed Chapter 797 standards for sterile compounding, recognizing that the proposed standards allow for the continued compounding of allergen extract prescription sets for individual patients while including some new requirements.
Get more information:
- Find out more about allergen extract compounding and USP Chapter 797.
- Read the submitted comments.
- Review the proposed standards for compounding allergen extracts in USP’s draft.
- Review existing standards in the Immunotherapy Practice Parameter.
You can also submit your own comments to USP by Nov. 30, 2018.
The College, AAAAI and AAOA will continue to fight for our members to continue to compound allergen extracts in the office setting for individual prescription sets. We will keep you posted as the USP process continues, and of any new developments impacting allergen immunotherapy from other agencies or organizations.